Skip to main content
. 2016 Mar 9;7(16):22064–22076. doi: 10.18632/oncotarget.8017

Figure 3. Overview of overlapping FDA approved drug recommendations at multiple levels.

Figure 3

(A) 75 metastatic breast cancer specimens grouped by maximum level of overlapping FDA approved drug recommendation(s) for any of its mutated genes. (B) Venn diagram showing relationship between four recommendation sources (FoundationOne, Drug Gene Interaction Database, Personalized Cancer Therapy and cBioPortal) with mutated genes in sample specimen # 37 [KIT, GNAS, KRAS, TOP1, AURKA, BRCA2, JAK2, SMAD4, TP53, ZNF217] based on maximum overlapping FDA approved drug recommendation(s). (C) Table listing all mutated genes for sample specimen # 37 (column 1), their FDA approved drug recommendations (column 2), sources identified by green check mark (column 3–6) and a colored background that corresponds with maximum overlapping drug(s) represented in (B).